The FDA approved a new oral GLP-1 this month, Foundayo, and for the first time in a while there's genuinely something different to offer patients who won't do injections.
Not better across the board. Different, and that distinction matters. Orforglipron, the active ingredient, is a non peptide GLP-1 receptor agonist, meaning it doesn't need the same narrow absorption window oral semaglutide requires. You can take it with food, without food, whenever fits your day. For a specific group of patients, that removes the main thing that was keeping them from starting. For everyone else, the medications that already exist still produce stronger results. Worth saying early, because approval announcements tend to get more enthusiasm than that nuance supports.
Worth noting: we're only weeks into prescribing this outside of a trial setting. ATTAIN-1 ran 36 weeks in a controlled environment. What I'll actually see in my clinic over the next year, how insurance handles it, whether adherence holds outside a trial, whether the real world side effect profile tracks the published data, those are still open questions. What follows is what the evidence says. Reality catches up to the data over time.
What Foundayo Brings to the Table
In ATTAIN-1, patients lost an average of 12.4% of body weight over 36 weeks, compared to 2.0% in the placebo group. The published results quote "a mean percentage change in body weight of −12.4% at week 36 in the orforglipron group." That's a real result. Not the strongest in the class, but for a pill with no food restrictions, it's enough to matter clinically.
Oral Wegovy delivers around 15% average weight loss, meaningfully higher. The tradeoff is a strict empty stomach requirement every morning, which works fine for some patients and quietly derails others within the first few months. For patients who tried oral semaglutide and couldn't stick with that routine, or who have irregular schedules, or who travel a lot, Foundayo removes a genuine barrier. For anyone still considering injections, tirzepatide remains the strongest approved option by a margin that's hard to argue around.
The Waiting Problem
Every time something new gets approved or makes news, the same pattern plays out. Patients who've been on the fence decide to keep waiting, figuring something better is just around the corner. Sometimes they're right. More often they're not, and the waiting has real costs that don't show up in any press release.
This year the thing people are waiting for is retatrutide. Phase 3 TRIUMPH-4 data showed 28.7% average weight loss, higher than anything currently approved. Some patients have told me they're holding out for the FDA decision, which is estimated around 2027. A few months into that wait, for some of them, metabolic markers are already moving in the wrong direction. The drug they're waiting for won't undo that.
Start with what exists and what actually fits your life. Adjust when better options arrive. That's really how this works.
What's Coming, and What's Worth Watching
Retatrutide (Eli Lilly) is the most interesting candidate in development, by a significant distance. It's a triple agonist, GLP-1, GIP, and glucagon receptors simultaneously, and Phase 3 TRIUMPH-4 data showing 28.7% weight loss extends the efficacy ceiling well beyond what tirzepatide delivers today. Eli Lilly describes it as targeting "three distinct hormonal pathways involved in energy intake and expenditure." FDA timeline is estimated around 2027, though that date can and usually does move. If the results hold through review, this is the drug that changes the conversation.
Amycretin (Novo Nordisk) is a GLP-1 and amylin combination being developed as both an injection and a pill. Phase 3 trials started in early 2026. The oral version is the development worth watching, if the formulation delivers competitive results without the food restrictions of oral semaglutide, that's meaningful. Timeline is probably 2028-2029 at earliest.
Aleniglipron (Structure Therapeutics) is an oral non peptide GLP-1 in Phase 2, earlier stage, different molecular approach than orforglipron. Less certain outcome, but part of a broader push toward oral options with higher efficacy ceilings.
None of these are available. Retatrutide is worth following closely. The others are worth knowing about.
What the 2026 Approval Changed in Clinic
The short version of 2026 so far is that the prescribing mix has already shifted. Before Foundayo, patients who wanted oral had one realistic option and it came with a food rule that many could not live with. The alternative was not prescribing at all, or pushing toward an injection they had already said no to. Now there is a second oral on formulary at most pharmacies, and the triage conversation in a new patient visit takes longer because the options fan out wider than they did six months ago.
A few practical things have come up in the first weeks of prescribing Foundayo. Patients are tolerating the titration schedule about as well as the trial data suggested they would. The nausea curve in the first month is tracking what ATTAIN-1 showed, mild to moderate in most cases, front loaded, fading by week six or so for most patients. Dose escalation is moving on the expected timeline. No early warning signals of the kind that sometimes emerge post marketing, though six weeks is far too short to draw any real conclusion there. Long term safety and durability data will come from registries over the next few years.
The insurance story is messier. Most commercial plans have added Foundayo to formulary with prior authorization attached. Medicare still won't cover any obesity indication, a policy problem that a new drug approval doesn't fix, and that leaves many older patients either paying cash or staying on whatever their plan does cover for related conditions. Manufacturer savings programs have helped close some of that gap, and the cash price through direct to patient programs falls within the range most patients on injectable GLP-1s are already paying out of pocket.
The Drugs I Am Watching Most Closely
Among everything in the pipeline, there are three candidates I actually check on most weeks. Retatrutide is the one that matters most. Phase 3 TRIUMPH-4 data showed 28.7% average weight loss, higher than anything currently approved. If the trials read out cleanly, the FDA decision could land in 2027, and that would push the efficacy ceiling of this whole drug class up by several points. The mechanism, a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, is different enough from existing approvals that it may produce responses in patients who didn't do well on the current generation of GLP-1s.
Amycretin is the other one I watch. It combines GLP-1 activity with amylin agonism, a pairing that produced Phase 1 numbers in the 22 percent range at high doses. Those were small trials and short, so the Phase 3 numbers may come in lower, but the early signal was strong enough that Novo accelerated it into Phase 3 trials. Estimated approval is 2028 or 2029.
CagriSema sits in between. The NDA was filed in late 2025, Phase 3 data showed roughly 22.7 percent weight loss, and an FDA decision is expected late 2026. It is a meaningful bump over Wegovy but a smaller bump than retatrutide would be, and it comes from a combination of semaglutide and cagrilintide rather than a new mechanism entirely.
Where Things Stand Right Now
2026 has more options than 2025 did. Foundayo is a real addition for a real group of patients. The pipeline is genuinely promising, more so than it's been at any point in this field's history. But none of that changes the basic math: tirzepatide is still the strongest approved option by the numbers, and starting something that exists tends to beat waiting for something that doesn't yet.
If you've been avoiding weight loss medication because injections weren't an option and oral semaglutide's morning routine didn't fit your life, Foundayo is genuinely worth a conversation with your doctor. If you've been holding out for retatrutide, have that conversation now about what currently exists, and revisit the math when the FDA actually rules.
